Category Archives: Cell Biology

ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital – Business Wire

SAN DIEGO & OXFORD, England--(BUSINESS WIRE)--ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, today announced the closing of a $75 million Series B financing. The round was led by ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, also participated in the round.

ONIs technology democratizes cutting-edge science, enabling researchers to develop new angles to explore and understand the complexity of biological systems at super-resolution, said Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners. The more we understand about these intricate systems, the closer we will get to engineering biology. This single-molecule information and the light it sheds on disease mechanisms will allow possibilities that were previously unimaginable in the design of novel therapeutics and diagnostics.

Innovative tools that drive biological insights and technologies to elucidate cell biology at high resolution represent the next critical wave of discovery and application, said Shaun Rodriguez, Director of Life Science Research at Casdin Capital. Realizing this immense opportunity requires technologies that are readily accessible to many researchers, and the talented team at ONI are uniquely capable of driving broad adoption of this platform to disrupt large and important end markets.

Since our founding, we have placed over 120 Nanoimagers and have empowered over 650 scientists with accessible single molecule technology, said Bo Jing, founder & CEO of ONI. We are proud that our products have added unique insights to the biomedical research of our customers and that they have accumulated more than 110 scientific publications over the past several years, with that number rapidly rising. I would like to thank all of our investors for their solidarity with ONIs mission to democratize this fundamental discovery tool. We look forward to learning from Keith and Shaun who have joined our board and welcome their guidance for the next phase of growth.

Proceeds from the financing will be used to grow ONIs commercial and R&D teams in the US and Asia, driving technology adoption in those geographies. Funds will also be used to expand ONIs portfolio of consumables and cloud-based software apps; working together, they become end-to-end automated solutions for application verticals. The first two applications are in the space of extracellular vesicles and cell therapy, especially chimeric antigen T-cell (CAR-T) therapy. In both cases, ONI brings superior sensitivity and true quantification to the detection of protein biomarkers, down to a single copy of a protein, and provides the capability to spatially and temporally resolve the position of these biomarkers with 20 nm accuracy.

This data will help biotech and pharma companies create more efficacious and better targeted therapies and identify spatial scales across large complex structures down to single molecules. This ability to put the building blocks of life into large scale context will generate breakthroughs across the life sciences spectrum, including neuroscience, epigenetics, virology, immuno-oncology, drug development, diagnostics and vaccine development. ONI has customers in all of these diverse biomedical areas already and anticipates growing its customer base by releasing targeted and streamlined solutions for each field.

In addition to the new financing, ONI announced an expanded executive team. Together with founder & CEO, Bo Jing, the team now comprises:

Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners, and Shaun Rodriguez, Director of Life Science Research at Casdin Capital, have joined ONIs board of directors in addition to Patrick Finn, Chief Commercial Officer at Twist Bioscience who joined in 2021.

About ONI

ONI is a rapidly growing company with offices in San Diego, CA (HQ) and Oxford, UK. ONIs first product, the Nanoimager, is the worlds first desktop, super-resolution, single-molecule imaging platform capable of visualizing and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution. ONI was founded in 2016 as a spin-out of Oxford University. For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI.

About ARCH Venture Partners

ARCH Venture Partners invests in advanced technology companies and is one of the worlds leading early-stage technology venture firms. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

For more information, visit http://www.archventure.com.

Follow this link:
ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital - Business Wire

Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022 – Yahoo Finance

MARSEILLE, France, January 24, 2022--(BUSINESS WIRE)--Regulatory News:

Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at January 1, 2022:

Total number of shares outstanding:

79,542,627 ordinary shares

6,514 Preferred Shares 2016

7,581 Preferred Shares 2017

Total number of theoretical voting rights (1):

80,300,467

Total number of exercisable voting rights (2):

80,281,892

(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2.

(2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Story continues

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at http://www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code

FR0010331421

Ticker code

Euronext: IPH Nasdaq: IPHA

LEI

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys commercialization efforts, the Companys continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Companys business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharmas website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Companys Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220123005086/en/

Contacts

For additional information, please contact:

Investors

Innate Pharma Henry Wheeler Tel.: +33 761 88 38 74 Henry.wheeler@innate-pharma.fr

Media

Innate Pharma Tracy Rossin (Global/US)Tel.: +1 240 801 0076Tracy.Rossin@innate-pharma.com

ATCG Press Marie Puvieux (France)Tel.: +33 (0)9 81 87 46 72innate-pharma@atcg-partners.com

Link:
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022 - Yahoo Finance

Asher Bio Expands Leadership Team with Three Key Appointments – Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the expansion of its executive leadership team with the appointments of Don OSullivan, Ph.D., M.B.A., as Chief Business Officer, James Cross, Ph.D., as Vice President, Regulatory Affairs and Florence Zhu, CPA, as Vice President, Finance. Together, these leaders will support the companys growth and further enhance its ability to advance a growing pipeline of highly differentiated precision immunotherapies through research and development.

We are delighted to welcome Don, Jamie and Florence to Asher Bio, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio. Each is a highly talented industry veteran, with experience building high quality and successful biotechnology companies and advancing clinical pipelines in oncology in a manner consistent with our core values. We look forward to their many contributions as we continue to make significant progress across our business, with the potential to advance two oncology programs into clinical development over the next two years, while collaborating to broaden our cis-targeted programs into the areas of cell therapy augmentation, autoimmune and infectious diseases.

Don OSullivan, Ph.D., M.B.A., Chief Business Officer

Dr. OSullivan brings nearly 15 years of leadership experience in biotechnology and pharmaceutical business development. Dr. OSullivan joins Asher Bio from Roche and Genentech, where he served most recently as Vice President, Global Head of Oncology Partnering, with responsibility for all oncology pipeline business development activities. Earlier, Dr. OSullivan held positions of increasing responsibility at Genentech, including leading partnering efforts for gREDs Immunology and Infectious Disease R&D groups. Dr. OSullivan holds a Ph.D. in Molecular Biology from the University of Cambridge, an M.B.A. in Healthcare and Finance from the Wharton School at the University of Pennsylvania, and a B.Sc. in Biochemistry from Imperial College London.

I am incredibly excited by the modularity of Asher Bios platform, which enables the rapid generation and de-risking of new molecules against a diverse set of immune cell types, spanning multiple therapeutic areas, said Dr. OSullivan. Over the course of my career, I have developed a deep appreciation of the need for more selective medicines for the treatment of cancer, autoimmune and infectious diseases, which can deliver robust efficacy without introducing significant off-target toxicity. I am eager to leverage my experience to maximize the reach of Asher Bios cis-targeted technology and ultimately enable many more patients to achieve better clinical outcomes.

James Cross, Ph.D., Vice President, Regulatory Affairs

Dr. Cross is an established industry veteran, with nearly 20 years of experience working in industry, academia and at the U.S. Food and Drug Administration (FDA). Prior to Asher Bio, Dr. Cross founded and served as the principal regulatory consultant of Cross BioStrategies, LLC, where he assisted companies with product development strategies, regulatory filings, and regulatory leadership. Earlier, he served as Executive Director of Regulatory Affairs at Halozyme Therapeutics, leading product strategy for assets in global late-stage oncology development, and as Head of Regulatory Affairs at Forty Seven Inc. (acquired by Gilead Sciences, Inc.), where he supported the clinical program expansion for the companys lead asset, magrolimab, while managing the regulatory, quality assurance and medical writing functions. Dr. Cross started his industry career in roles of increasing responsibility at Genentech, after working for five years at the FDA. Dr. Cross holds a Ph.D. in Health Outcomes Research from the University of Washington, an M.S. in Immunology from the University of California at Davis, and a B.S. in Biology and French from Tufts University.

I am honored to join the talented team at Asher Bio at this important moment, as the company prepares to file its first investigational new drug application to advance AB248 into clinical development, said Dr. Cross. I am impressed by the compelling anti-tumor activity that has been observed across multiple preclinical models and believe AB248 may offer a best-in-class IL-2 immunotherapy. I look forward to partnering with the team on a clinical and regulatory strategy for AB248 that efficiently advances this program through development for the benefit of patients and their doctors.

Florence Zhu, CPA, Vice President, Finance

Ms. Zhu brings over 20 years of finance, financial reporting and public company management experience in the life sciences industry. Prior to joining Asher Bio, Ms. Zhu was the Vice President of Finance and Corporate Controller at Olema Oncology, where she made significant contributions to their public company transition and the establishment of their finance team. Earlier, she served as Senior Director, Corporate Controller at Forty Seven, Inc. (acquired by Gilead Sciences, Inc.) and at Five Prime Therapeutics (acquired by Amgen), and in roles of increasing responsibility at Codexis, Inc., Maxygen Inc., Varian Inc. and Guidant Corporation. Ms. Zhu is a Certified Public Accountant and holds a B.A. in Accounting from the State University of New York at New Paltz.

Over the last two years, Asher Bio has assembled an incredible team of industry leaders with a shared belief in the breakthrough potential of cis-targeted immunotherapies, as well as a strong investor syndicate to support the advancement of its lead product candidates, said Ms. Zhu. I am delighted to join Asher Bio and look forward to working with the team to establish a robust business organization that can serve as a foundation for long-term growth.

About Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit http://www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.

Continue reading here:
Asher Bio Expands Leadership Team with Three Key Appointments - Business Wire

Professor / Associate Professor in Biological Mass Spectrometry job with NORTHUMBRIA UNIVERSITY | 278565 – Times Higher Education (THE)

Northumbria University, Newcastle, is a research rich, business focused professional university with a growing global reputation for academic excellence. Colleagues are passionate about the principles and applications of Science and Technology in all its forms and strive for excellence in research, teaching and innovation.

Cellular and Molecular Sciences are an integral part of the Department of Applied Sciences research portfolio which was a significant part of the Universitys success in the Research Excellence Framework (REF) 2014 exercise, placing Northumbria in the top 50 UK universities for research power. Our REF 2021 submission, for which results are still awaited, once again had a significant contribution from academics working in this area.

The Department has particular strengths in biochemistry, chemistry, cell biology, immunology, microbiology, molecular biology and neuroscience, as well as a history of interdisciplinary research, often in collaboration with industry and with UKRI co-funding.We are looking for outstanding candidates that can demonstrate a track record in leading mass spectrometry research, as applied to biological samples of any type, but which would aid collaboratory research within the departments research portfolio. Applicants will be expected to be able to outline in their applications their plans on how their research and expertise would extend and complement the Departments research portfolio and build upon its existing research strengths.

The Department has state-of-the-art facilities for research, including recently refurbished, well-equipped laboratories for biochemistry and molecular biology, chemistry, microbiology, and tissue culture lab. The post holder will have access to state-of-the-art mass spectrometry instrumentation including an Orbitrap ID-X, Time-of-Flight, Ion Trap and Quadrupole-based mass spectrometers, and associated separation techniques including GC, HPLC, GPC and ion mobility spectrometry. to The department also has a suite of elemental analysis equipment including inductively coupled plasma atomic emission spectroscopy and X-ray fluorescence spectroscopy. The department also possesses a microscopy suite that includes fluorescence, laser, polarised light, confocal and infra-red microscopy with the expectation of significant expansion in cellular imaging techniques. This iscomplemented by a dedicatedMulti-Omics facility including; genomics (Illumina, Oxford Nanopore and Pacific Biosciences platforms), metabolomics and proteomics (Thermo Orbitrap ID-X Tribid and Q-exactive Mass Spectrometers) allied to dedicated high-performance computing.

Supporting 80 academics, 20 research fellows and 40 PhD students, the multi-disciplinary breadth and depth of the Department provides extensive opportunities for forming collaborative working relationships for new colleagues. Details of our research groups and themes can be foundhere. The Research England funded Hub for Biotechnology in the Built Environment (HBBE) at Northumbria University has brought significant investment in new staff and facilities demonstrating the Departments commitment to ground-breaking transdisciplinary research.

Working within the Department of Applied Sciences, your role will involve both teaching and research.As a senior academic colleague, you will assist the Department Leadership Team to maintain, enhance and improve the Universitys national and international reputation in your academic field. You must demonstrate continuing academic attainment and achievement. You will also provide academic leadership (of your subject and associated colleagues), through active contribution to your discipline and to the life and work of the Department and the wider University.

To be successful in this role you will have externally recognised research outputs of a quality that are internationally excellent in terms of originality, significance and rigour, and demonstrable success in securing research funding. You should also demonstrate academic leadership experience, strong standing with external bodies and networks in your field and a detailed plan for future external funding acquisition

For informal enquiries about this post, please contact Professor Justin Perry email:justin.perry@northumbria.ac.uk

To apply for this vacancy please click Apply Now,and submit a covering letter, a CV that includes your research focus, areas that you can teach across all our undergraduate and postgraduate bioscience courses, any current or planned funding applications and a full publication list.Please highlight your highest quality research outputs up to a maximum of 4. In addition, candidates are asked to provide copies of the top 2 research outputs (Journal / book chapter /practice-based portfolio). Where possible candidates are asked to combine all of these documents into a single file.

Northumbria University takes pride in, and values, the quality and diversity of our staff. We welcome applications from all members of the community.The University holds an Athena SWAN Bronze award in recognition of our commitment to improving employment practices for the advancement of gender equality and is a member of theEuraxessnetwork, which delivers information and support to professional researchers.

We welcome applications from the UKand across the world. Visit our web pages for details about theRelocation Assistance Scheme

Please note this vacancy will close on 13/02/2022

Originally posted here:
Professor / Associate Professor in Biological Mass Spectrometry job with NORTHUMBRIA UNIVERSITY | 278565 - Times Higher Education (THE)

Obtain the booster to prevent another wave- Health Authorities – Newsfirst.lk

COLOMBO (News 1st); Public should obtain the booster vaccine as soon as possible to avoid another COVID-19 wave, saysPhysiotherapist at the Colombo North Teaching Hospital,Prof. Sharmila de Silva.

Pointing out that although hospitals are not overcrowded as of yet and the death toll has not shown a substantial increase, Prof. de Silva stated that the number of patients reported each day is increasing, and the rate of new COVID-19 cases being reported in the country has risen sharply as well.

This sharp rise was noted amidst reports that the OMICRON variant becoming the fastest spreading variant in the country.

The Allergy, Immunology and Cell Biology Unit of the University of Sri Jayewardenepura also stated that two sub-lineages of the variant are spreading rapidly.

Emphasizing that many people who obtained the first and second dose of the vaccine do not show the same amount of enthusiasm to obtain the third dose, Prof. de Silva mentioned that several myths regarding the vaccine have rooted in society, such as other side-effect diseases being reported due to the vaccine or infertility and impotence being a side effect of the vaccine.

Requesting the public to not to believe in such myths, Prof. de Silva reiterated that every single person must obtain the booster dose to prevent another wave of COVID-19 in the country.

Go here to read the rest:
Obtain the booster to prevent another wave- Health Authorities - Newsfirst.lk

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference – StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo

Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baseline disease severity increases

Data and analyses support the potential for a highly competitive efficacy and safety profile for CBP-201 that includes a differentiated Q4W dosing schedule

SAN DIEGO, CA and TAICANG, China, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the Company), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that data from the global Phase 2b clinical trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermatitis (AD) (WW001) (NCT04444752), will be presented in two abstracts and posters at the Maui Derm Conference that begins today, January 24th, and ends January 28th, in Maui, Hawaii.

The abstracts and posters will expand on the topline results reported by the Company on January 5, 2022, which demonstrated that CBP-201 met the primary and key secondary efficacy endpoints of the trial, with favorable safety data reporting low incidences of injection site reactions, conjunctivitis and herpes infections.

The abstracts and posters will also provide detail of the analyses performed by the Company of patients within the trial with higher baseline disease severity that more closely approaches the disease severity in Phase 3 trials of the approved IL-4R agent. These analyses consistently demonstrate increased efficacy as baseline disease severity increases, indicating that CBP-201 has the potential for a highly competitive efficacy and safety profile that includes a differentiated Q4W dosing schedule.

Poster Presentation Details

Title: Efficacy and Safety of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD): A Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

Presenter: Bruce Strober

Title: The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001).

Presenter: Jonathan I. Silverberg

Both posters will be available on the Presentations and Publications section of the Connect Biopharma website Monday, January 24, 2022: https://www.connectbiopharm.com/our-science/presentations-and-publications/.About Atopic DermatitisAtopic dermatitis (AD), which has an estimated lifetime prevalence of up to 20% and is increasing globally, is the most commonly diagnosed chronic inflammatory skin disorder. It is characterized by skin barrier disruption and immune dysregulation. Estimates of prevalence of AD in China show an increase over time and recent longitudinal studies have reported a dermatologist-diagnosed prevalence of 7.8% in Chinese outpatients visiting tertiary hospitals. In the United States, it is estimated that 26.1 million people have AD, of which 6.6 million have moderate-to-severe disease. Further, over 58% of adults with moderate-to-severe AD have disease that physicians consider to be inadequately controlled by approved therapeutic modalities, including topical anti-inflammatory agents and systemic agents.

About CBP-201CBP-201, discovered internally using Connect Biopharma's proprietary Immune Modulation Technology Platform, is an antibody designed to target interleukin-4 receptor alpha (IL-4R), which is a validated target for the treatment of several inflammatory diseases, including atopic dermatitis (AD). CBP-201 was well tolerated and showed evidence of clinical activity in a Phase 2b clinical trial (NCT04444752) in adult patients with moderate-to-severe atopic dermatitis, suggesting a potential for a differentiated efficacy profile compared with data from clinical trials of the current biologic standard of care therapy. CBP-201 is also being evaluated in a China specific pivotal trial in adults with moderate-to-severe atopic dermatitis (NCT05017480); in a Phase 2b trial in adult patients with moderate-to-severe persistent asthma (NCT04773678); and in a Phase 2b trial in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT04783389).

About Connect Biopharma Holdings LimitedConnect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

Our lead product candidate, CBP-201 an antibody designed to target interleukin-4 receptor alpha (IL-4R) has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohns disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 a peripherally acting antagonist of histamine receptor 3 for the treatment of pruritus associated with AD.

With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at http://www.connectbiopharm.com

FORWARD-LOOKING STATEMENTSConnect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Companys statements regarding the potential of CBP-201 to achieve a differentiated, competitive, or favorable benefit or profile including with respect to safety, efficacy and/or convenience, and the Company's plans to initiate a Phase 3 trial program to further evaluate CBP-201. The inclusion of forward-looking statements shall not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the Connect Biopharma business and other risks described in the Company's filings with the Securities and Exchange Commission (SEC). Among other things, there can be no guarantee that planned or ongoing studies will be initiated or completed as planned, that future study results will be consistent with the results to date, that CBP-201 will receive regulatory approvals, or be commercially successful. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Connect Biopharma undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharma's filings with the SEC which are available from the SECs website (www.sec.gov) and on Connect Biopharmas website (www.connectbiopharm.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

IR/PR Contacts:Lazar FINN PartnersDavid Carey(IR)T: +1-(212) 867-1768david.carey@finnpartners.comErich Sandoval (Media)T: +1-(917)-497-2867erich.sandoval@finnpartners.comCorporate Contacts:info@connectpharm.com

Excerpt from:
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference - StreetInsider.com

City of Hope and CytoImmune announce study demonstrating novel off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell-based therapy…

DUARTE, Calif. & TOA BAJA, Puerto Rico--(BUSINESS WIRE)--City of Hope, a world-renowned cancer research and treatment organization, and CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of natural killer (NK) cell-based cancer therapies, today announced a study published in the high-impact journal Gastroenterology that demonstrates off-the-shelf anti-prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) NK cells significantly suppressed pancreatic cancer in vitro and in vivo using a method known as freeze-thaw.

The therapy PSCA CAR_s15 NK cells, also known as CYTO NK-203 persisted more than 90 days after infusion and significantly prolonged the survival of mice with pancreatic cancer, showing that the freeze-thaw method works. For the study, PSCA CAR_s15 NK cells were produced and then frozen. The cells were then thawed and used in preclinical studies at City of Hope.

Our patients need additional ways to attack their pancreatic cancer. The work presented by City of Hopes team is distinctive and promising for two reasons: First of all, it is based on a precision medicine approach that is a special target in the patient's pancreatic cancer PSCA. Secondly, it is an immunologic approach, using human natural killer cells, which are specifically engineered to attack the patient's cancer. These findings should be accelerated to a clinical trial as rapidly as possible, said Daniel D. Von Hoff, M.D., a distinguished professor in the Molecular Medicine Division of the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. He also is senior consultant-clinical investigator at City of Hope and is one of the nations leading authorities on the treatment and care of pancreatic cancer patients.

City of Hope is committed to finding more effective and innovative treatments for difficult-to-treat solid cancers, and pancreatic cancer is clearly one of them, said Saul Priceman, Ph.D., assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope and a study author. These new PSCA CAR_s15 NK cell preclinical studies provide tremendous support for the anticipated upcoming clinical trials to evaluate efficacy and safety of this novel CAR-engineered NK cell therapy in patients with pancreatic cancer, which is a promising expansion of our existing clinical programs that target PSCA in solid cancers using CAR-engineered T cell therapy.

Pancreatic cancer is the third leading cause of cancer-related death in the United States with a five-year survival rate of approximately 10%. The cancer is typically detected when it is at a late stage and incurable. Chemotherapy or other therapies provide modest benefit. Therefore, the development of new therapies for pancreatic cancer is crucial. The therapy can also be used for other PSCA+ cancers, such as stomach and prostate.

NK cell technology works by using natural killer cells from a patient or donor. NK cells are then engineered so they express a receptor a CAR that is specific for a protein expressed by cancerous cells, along with the secretion of IL-15, which sustains the survival of the NK cells.

Christina Coughlin, M.D., CEO of CytoImmune Therapeutics, said, "We are excited to share this data on our CAR NK candidate for pancreatic cancer. This foundational data supports robust anti-tumor activity with CYTO NK-203, making us confident our innovative and off-the-shelf NK cell therapy approach has the potential to deliver more accessible, safe and effective cell-based treatment options to cancer patients. We are encouraged by these findings and look forward to continuing our work with City of Hope in order to move this initiative to the clinic.

This immunotherapy is revolutionizing the treatment of some blood cancers; however, its use in the treatment of solid tumors has been limited, in part because most of the proteins currently used to target CAR cells to solid tumors are present in low levels on other normal tissues, leading to toxic side effects.

Based on research by Michael Caligiuri, M.D., president of City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair, and Jianhua Yu, Ph.D., professor and director of the Natural Killer Cell Biology Research Program, who have nearly 55 years of collective laboratory investigation of NK cells, CytoImmune is developing an NK cell platform designed to overcome the limitations and challenges of current technologies for engineering NK cells. The platform is designed to generate an abundant supply of CAR NK cells from a single umbilical cord donor, engineered with the CAR for effective recognition of tumor targets, and secreting IL-15 to improve the persistence of CAR NK cells for sustained activity in the body. The process enables scientists to freeze, transport and store engineered CAR NK cells for off-the-shelf use for the treatment of cancer.

The study titled Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer can be found here.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHopeTM, a subsidiary launched in 2019, serves employers and their health care partners by providing access to NCI-designated cancer center expertise. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

About CYTO NK 203

CYTO NK-203 is an off-the-shelf allogeneic CAR NK cell therapy derived from umbilical cord blood, expressing a CAR against prostate stem cell antigen and soluble IL-15 and engineered with proprietary features designed to improve the safety and efficacy of NK cells as a potential therapy.

About CytoImmune Therapeutics Inc.

Founded in 2017, CytoImmune Therapeutics is a clinical-stage biotechnology company, focused on developing an innovative and differentiated pipeline of NK cell therapies, using proprietary, robust and well characterized NK cell expansion and engineering technologies pioneered by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D. The pipeline includes cytokine induced NK (CI-NK) for lung cancer, FLT3 CAR-NK for acute myeloid leukemia, PSCA CAR-NK cells for solid tumors and GPRC5D BiKE secreting BCMA CAR-NK cells for multiple myeloma. CytoImmunes lead product, CYTO-102 (CI-NK) cell therapy, aims to enter the clinic in combination with atezolizumab (anti-PD-L1 monoclonal antibody) for nonsmall cell lung cancer in 2022.

Here is the original post:
City of Hope and CytoImmune announce study demonstrating novel off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell-based therapy...

Genetic Research Shows Rapid Immune Response in Children Protects Them From COVID-19 – SciTechDaily

Discovery of importance of interferon response in preventing serious infection will underpin new diagnostics and therapeutics.

Fundamental differences in the immune response of adults and children can help to explain why children are much less likely to become seriously ill from SARS-CoV-2, according to new research from the Wellcome Sanger Institute, University College London, and their collaborators.

The study, published in the journal Nature, is the most comprehensive single-cell study to compare SARS-CoV-2 infection in adults and children across multiple organs. Researchers found that a stronger innate immune response in the airways of children, characterized by the rapid deployment of interferons, helped to restrict viral replication early on. In adults, a less rapid immune response meant the virus was better able to invade other parts of the body where the infection was harder to control.

As part of the Human Cell Atlas1 initiative to map every cell type in the human body, the findings will be a valuable contribution to predict personal risk from SARS-CoV-2. A nasal swab to measure the immune response in newly infected adults could be used to identify those at higher risk who may be candidates for pre-emptive monoclonal antibody treatment. Recent research has also suggested inhalation of interferons could be a viable therapy2.

The immune system that we are born with is not the same as the one we have as adults. The innate immune system of children is better able to recognize dangerous viruses or bacteria automatically, triggering nave B and T cells that can adapt to the threat. Adults have a more adaptive immune system containing a huge repertoire of memory B and T cell types, which have been trained through past exposure to respond to a particular threat3. Though the adult immune system also has an innate response, it is more active in children.

One of the key mechanisms of both immune systems is a group of proteins called interferons, which are released in the presence of viral or bacterial threats and tell nearby cells to tighten their defenses. Interferons are proteins with strong anti-viral activity and their production will typically lead to the activation of B and T cells, which kill infected cells and prevent the pathogen from spreading further.

For this study, researchers at University College London (UCL) and affiliated hospitals4 collected and processed matched airway and blood samples from 19 pediatric and 18 adult COVID-19 patients with symptoms ranging from asymptomatic to severe, as well as control samples from 41 healthy children and adults.

Single-cell sequencing of the samples was done at the Wellcome Sanger Institute to generate a dataset of 659,217 individual cells. These cells were then analyzed, revealing 59 different cell types in airways and 34 cell types in blood, including some never previously described.

Analysis showed that interferons were more strongly expressed in healthy children compared to adults, with a more rapid immune response to infection in childrens airways. This would help to restrict viral replication early on and give children an immediate advantage in preventing the virus from infecting the blood and other organs.

Because SARS-CoV-2 is a new virus, it isnt something that the adaptive immune system of adults has learned to respond to. The innate immune system of children is more flexible and better able to respond to new threats. What we see at a molecular level are high levels of interferons and a very quick immune response in children that helps to explain why they are less severely affected by COVID-19 than adults.

Dr. Masahiro Yoshida, University College London

The study also detailed how the immune system of adults, with its high numbers of killer immune cells such as B and T cells, can work against the body once SARS-CoV-2 has spread to other parts of a patient.

Compared to children, adult blood has a greater number and variety of cytotoxic immune cells, which are designed to kill infected cells to prevent an infection spreading. But it is a fine line between helping and hindering. Once the virus has spread to several areas of the body, organ damage can be caused by the immune system trying and failing to control the infection. Our study shows that not only do children respond better initially, if the virus does enter the blood the cytotoxic response is less forceful.

Dr. Marko Nikolic, University College London

Knowing exactly how and why the immune response to SARS-CoV-2 can fail to control the infection or start to harm the body provides scientists with the means to start asking why certain individuals may be at greater risk of serious illness.

These data suggest that newly diagnosed adults could be tested to check interferon levels in the airway. Higher interferon levels, similar to those found in children, would suggest a lower risk of severe disease, whereas low interferon levels would suggest higher risk. Higher risk patients could then be considered for pre-emptive treatments such as monoclonal antibodies, which are expensive and can be in limited supply.

To put it simply, the innate immune response is better at fighting COVID-19 and children have stronger innate immunity, but immunity is also a complex ballet involving many types of cells. The timing and the types of cells that are triggered will influence how an infection develops, and this will vary between individuals for all sorts of reasons in addition to age. Some of the differences we observe between children and adults may help us to think about how we gauge personal risk for adults as a way of mitigating serious illness and death.

Dr. Kerstin Meyer, Wellcome Sanger Institute

In addition, there is growing evidence of the therapeutic benefits of inhaled interferon beta 1a. Based on the study results, this should be particularly the case for patients with weak or absent interferon activation.

The results are insightful not only for addressing COVID-19, but more broadly for understanding changes in the airway and blood throughout childhood. They demonstrate the power of single-cell resolution to reveal differences in the biology of children and adults, while pointing to very different considerations when thinking about how a specific disease arises and may be treated.

Jonah Cool, Chan-Zuckerberg Initiative

Reference: Local and systemic responses to SARS-CoV-2 infection in children and adults by Masahiro Yoshida, Kaylee B. Worlock, Ni Huang, Rik G. H. Lindeboom, Colin R. Butler, Natsuhiko Kumasaka, Cecilia Dominguez Conde, Lira Mamanova, Liam Bolt, Laura Richardson, Krzysztof Polanski, Elo Madissoon, Josephine L. Barnes, Jessica Allen-Hyttinen, Eliz Kilich, Brendan C. Jones, Angus de Wilton, Anna Wilbrey-Clark, Waradon Sungnak, J. Patrick Pett, Juliane Weller, Elena Prigmore, Henry Yung, Puja Mehta, Aarash Saleh, Anita Saigal, Vivian Chu, Jonathan M. Cohen, Clare Cane, Aikaterini Iordanidou, Soichi Shibuya, Ann-Kathrin Reuschl, Ivn T. Herczeg, A. Christine Argento, Richard G. Wunderink, Sean B. Smith, Taylor A. Poor, Catherine A. Gao, Jane E. Dematte, NU SCRIPT Study Investigators, Gary Reynolds, Muzlifah Haniffa, Georgina S. Bowyer, Matthew Coates, Menna R. Clatworthy, Fernando J. Calero-Nieto, Berthold Gttgens, Christopher OCallaghan, Neil J. Sebire, Clare Jolly, Paolo de Coppi, Claire M. Smith, Alexander V. Misharin, Sam M. Janes, Sarah A. Teichmann, Marko Z. Nikolic and Kerstin B. Meyer, 22 December 2021, Nature.DOI: 10.1038/s41586-021-04345-x

This research was funded by Wellcome, the Chan Zuckerberg Initiative, Rosetrees Trust, Action Medical Research, Medical Research Council and the European Unions Horizon 2020 program.

Visit link:
Genetic Research Shows Rapid Immune Response in Children Protects Them From COVID-19 - SciTechDaily

Locations where Omicron has been found in Sri Lanka so far – NewsWire

According to the latest SARS-CoV-2 variant report issued by the Allergy Immunology and Cell Biology Unit of the Department of Immunology and Molecular Medicine of the University of Sri Jayewardenepura, 75 new cases of Omicron and 3 new cases of Delta were detected from 78 samples.

These 78 samples were sequenced from the 1st2ndand 3rdweeks of January from the community. said Dr. Chandima Jeewandara, Director of the Allergy, Immunology and Cell Biology Unit of the Faculty of Medicine.The 78 Omicron cases include a mix of the two main Omicron lineages BA.1 and BA.2.

Omicron sublineages were detected in the following locations. 56 cases of BA.1 were detected in Colombo, Avissawella, Borelesgamuwa, Homagama, Katugoda, Kosgama, Madapatha, Padukka, Parakudawa and Wellampitiya. 12 cases of BA.2 were detected in Avissawella, Badulla, Colombo, Galle, Konnawala, Mt Lavinia, Nugegoda, and from one passenger from India. 7 cases of B.1.1.529 were detected in Angoda, Colombo, Ruwanwella, Mt Lavinia, Nugegoda and Padukka.

Different Delta sublineages were detected in the following locations.1 case of AY.98 (Sri Lanka delta sub-lineage) was detected in Thalangama. 1 case of AY.104 (Sri Lanka delta sub-lineage) was detected in Kaduwela.1 case of B.1.617.2 was detected in Wellampitiya.

Currently, 8% of the sequences of Sri Lanka are BA.2, which was named as a variant of interest by the UK Health security agency.

Other variants identified within Sri Lanka are B.1.411: Sri Lankan variant,B.1.1.25,B.1.258,B.1.428,B.4, B.4.7,B.1.1.365,B.1.525,B.1, B.1.1.

Read more here:
Locations where Omicron has been found in Sri Lanka so far - NewsWire

A tribute to Eddy Fischer (April 6, 1920August 27, 2021): Passionate biochemist and mentor – pnas.org

Edmond (Eddy) Fischer was one of the great biochemists of the 20th and 21st centuries. He was also a gifted pianist, an avid mountain climber, and a pilot, a true man of the world who lived on three continents and spoke many languages fluently. Having spent his childhood in China and Europe, Eddy was formally schooled in Switzerland and began his studies at the University of Geneva in 1939, just as Hitler was invading Poland. After receiving his doctorate in Chemistry at the University of Geneva, he went to the California Institute of Technology, but was then quickly recruited to the fledgling Department of Biochemistry at the University of Washington in 1953 by Hans Neurath, where the mountains as well as the biochemistry were a big attraction. Seattle remained his home for the rest of his life, but the world was his home and his impact radiated across many continents.

In Seattle he met Edwin Krebs, who had been recruited in 1948, and in the next few years these two young scientists changed the course of history for all of us. They laid the foundation for a community of scholars that extended across the world and Eddy, in particular, became a friend and mentor to all of us. His sphere of influence extended well beyond those who trained directly in his laboratory. In the 1950s, Ed and Eddy built quickly on the foundation that was laid at Washington University in St. Louis by Gerty and Carl Cori, two other earlier transplants from Europe, and made a discovery that changed the world of biology and won them the Nobel Prize in Physiology or Medicine in 1992 (1). They discovered that proteins in cells are dynamically regulated by the covalent addition of a phosphate moiety from ATP, and that two enzymes catalyze the reversible addition and removal of the phosphates: a kinase and a phosphatase. Specifically, they showed that the activity of glycogen phosphorylase, the enzyme that breaks down glycogen by releasing a glucose-1-P moiety at each step, was activated by the addition of a single phosphate by an enzyme they called phosphorylase kinase. This discovery nucleated a family of enzymes that includes over 500 protein kinases that control much of biology, and this family has become a major target for drug discovery.

The three of us represent a community of scholars who were not directly trained by Eddy, but whose lives and careers were profoundly influenced by this extraordinary man. Here, we explore Eddys world when he was 50 years old; this was 1971, the midpoint of his life. Fifteen years earlier he had made the discoveries that would earn him the Nobel Prize. In the following decade, he was busy raising his young family and traveling to Europe and Israel, but he was also training a group of young international postdoctoral fellows who would set the world stage for the next generations. This included Philip Cohen, Ludwig Heilmeyer, and Shmuel Shaltiel. So where were we in 1971, and what lay ahead for Eddy Fischer in the next 50 years?

At the time of the discovery of protein phosphorylation as a regulatory mechanism, many new scientific concepts were emerging around the world. The Department of Biochemistry at the University of Washington, in addition to being the birthplace of protein phosphorylation, was a mecca for protein chemistry and protein sequencing. Across the Atlantic, at the Laboratory of Molecular Biology (LMB) in Cambridge, England, in addition to discovering the DNA double helix, we were learning about the structure and function of the proteins that are encoded by the DNA, while the Biochemistry Department at Cambridge University was focused on protein synthesis. Two Nobel Prizes in 1962 went to LMB scientists: Jim Watson and Francis Crick received the Nobel Prize for Physiology or Medicine for their discovery of the double helix, while Max Perutz and John Kendrew received the Nobel Prize in Chemistry for their crystal structures of myoglobin and hemoglobin. In 1962 the LMB, which was laying the foundation for molecular biology, had just moved from the Department of Biochemistry in Cambridge University to their new home on Hills Road. At the same time, in Paris, the concepts of protein allostery were being born. And in the early 1960s a completely new university, the University of California at San Diego, as well as the Salk Institute for Biological Studies, were founded in La Jolla, California. By the end of the 1970s these worlds converged in a profound way that was woven together by Eddy Fischer and Ed Krebs, and this network would continue to grow over the ensuing decades. Protein phosphorylation emerged as a major field that regulates biological function in all cells, and Eddy and Ed, the founders, continued as the undeniable leaders. Eddys impact continued well into the 21st century, reaching far beyond those who trained directly in his laboratory.

In the spring of 1964, I (J.-P.C.) was finishing my doctoral thesis at the Pasteur Institute in the laboratory of Jacques Monod, who was then head of the Service de Biochimie Cellulaire. One day, Jacques opened the door of his office into the laboratory with a distinguished and cheerful gentleman, and said to me, May I introduce your neighbor in the lab for the next few months? This was my first encounter with Eddy and the beginning of a lifelong friendship. Indeed, Jacques had the idea to place Eddys desk in a sort of telephone booth from where Jean Pierre was carrying out his research on threonine deaminase (2). There were a few such cubicles in his laboratory, which were specifically designed for private scientific discussions. We took advantage of this opportunity to begin an endless debate about the chemical and molecular mechanisms of protein regulation, a debate that lasted many decades until Eddys death in 2021. At the time I knew, of course, Eddys work with Ed Krebs on the regulation of glycogen phosphorylase by phosphorylation/dephosphorylation, and his main motivation to visit our laboratory was, as he says, to understand how this enzyme was activated by AMP. A change in the conformation was needed to account for its indirect, allosteric, effect on the protein! But what was it? A change of the state of aggregation of the protein or something else? Possible examples supporting the aggregationdissociation scheme were the dimerization of phosphorylase b into phosphorylase a, already reported by Eddy himself and similar to the dissociation of glutamate dehydrogenase into subunits provoked by NADH, as reported earlier by both Carl Frieden and Gordon Tomkins (3).

Jacques initially was supporting, yet with caution, the associationdissociation scheme. I was firmly opposed to it. I had never noticed any change in sedimentation velocity of threonine deaminase in the presence of its feedback inhibitor isoleucine or any deaminase ligand (4). A conformational change had to be involved, but more subtle than a change of aggregation. But what was it? In the discussions with Eddy, it took time for me to suggest to him what I had in mind! I had observed that in the presence of urea, threonine deaminase reversibly split into subunits and that inhibitors like isoleucine protect against dissociation, while activators like valine or allothreonine did the opposite: they enhance the dissociation. Thus, the idea emerged that a change in conformation would take place between discrete states of a common oligomeric aggregate, yet with differences in the strength of interaction between the constitutive subunits (without change in aggregation) (4). A given ligand would then selectively stabilize one of the states thereby mediating signal transduction (5, 6).

Eddy wanted to know how general the suggested model was. How might it apply to the phosphorylase system not only to the addition of a ligand, but also to the covalent addition of a phosphate? He later wrote, we (with Ed Krebs) had to wait five or six years for the Pasteur group to come up with their allosteric model of enzyme regulation (2). I may say that I was very pleased by what happened later, and in particular to discover the picture of Eddy and Ed standing together with a poster illustrating the mechanism of action of protein phosphorylation on phosphorylase (Fig. 1), which shows some similarities with the original diagram of my thesis work. After all, these discussions in the Pasteur cubicles had been rather fruitful. Of course, this was not the end.

Allosteric transitions. (Left) A page from Jean-Pierre Changeuxs thesis. Image credit: Changeux family. (Right) Eddy Fischer and Ed Krebs, decades later, speculating on the conformational changes that are induced by adding a phosphate. Image credit: American Society of Biochemistry and Molecular Biology.

Our friendship lasted decades. Both of us were for years on the Board of Scientific Governors of the Scripps Research Institute in La Jolla. This was a unique opportunity for us to meet regularly every year, to further discuss allostery, in particular in the brain, and to speak French together. Aware of the many difficulties the Pasteur Institute had to faceand still facesEddy was also systematically trying to find a manner, always elegant, to help us. Perhaps some kind of memorial of his 1964 visit? He remained a passionate and lifelong advocate for the Pasteur Institute.

Nothing was missing in our extraordinary friendship, which was a constant fight for good science, a deep free-thinking open humanism, and an eternal sense of FrenchSwiss humor. Unforgettable.

I (T.H.) first met Eddy Fischer in December 1979 at a meeting on protein phosphorylation and bio-regulation in Basel, where I had been invited to speak about our recent discovery of tyrosine phosphorylation, a new type of protein kinase activity associated with viral transforming proteins that can switch normal cells into cancer cells. In fact, in October that year, I had visited Seattle and spoken about tyrosine phosphorylation at a meeting between the groups at the Salk Institute and the Fred Hutchinson Cancer Research Center working on mechanisms of tumor virus transformation, but no one from the University of Washington was present. Of course, prior to 1979 I was well aware of the seminal work that Krebs and Fischer had done some 20 years earlier, which had shown that phosphorylation of glycogen phosphorylase stimulates its catalytic activity. Indeed, as a graduate student in the Department of Biochemistry in Cambridge in the mid-1960s, I had taught this key regulatory principle to the biochemistry undergraduates I supervised. At the Basel meeting, Eddy spoke about his work identifying two phosphorylation sites in the catalytic (C) subunit of cAMP-dependent protein kinase (PKA) (7). This was just 2 years before he reported the complete sequence of the PKA C-subunit, assembled the old-fashioned way, by protein sequencing (8). This sequence was the Rosetta stone that unlocked the basic design of all protein kinases, and its sequence became the template that allowed sequence gazers, like me, to demonstrate that nearly all eukaryotic serine/threonine kinases and tyrosine kinases are closely related in their catalytic domains, possessing a series of key conserved motifs that are essential for phosphate transfer (9).

From 1980 on, following the discovery that tyrosine residues, as well as serine and threonine residues, could be phosphorylated by a protein kinase (10), our paths crossed on innumerable occasions at meetings on protein phosphorylation and dephosphorylation at venues around the world. At one particularly memorable meeting, held in 1988 in Titisee, Germany, Eddys postdoctoral fellow, Nick Tonks, talked for the first time about his biochemical purification and characterization of the first phosphotyrosine-specific protein phosphatase (PTP), which led on to the discovery of a huge family of related PTPs (11, 12). It was typical of Eddy to let his postdoctoral fellowpresent the work, rather than taking the credit himself for this breakthrough discovery. From then on, and even after he had to close his laboratory in 1991, Eddys research was focused on the exciting new field of PTPs, and altogether he published 49 PTP papers, a fitting bookend to an amazing career. Even after he finally retired, Eddy was a fixture at phosphorylation meetings, keeping up with latest developments in the field. When he was 90, I asked Eddy to write the Foreword for a multiauthored book on signal transduction that I was coediting, and back came a lucid and thought-provoking piece on the history of the signal transduction field, but, more importantly, the problems still left to be solved (13).

Eddy was indeed a remarkable scientist, who inspired a whole generation of biochemists and cell biologists to work on protein phosphorylation.

Embedded within the early studies of Gerty and Carl Cori in the 1940s were two enzymes, the converting enzyme, subsequently referred to as phosphorylase kinase, and the phosphate removing (PR) enzyme, which became the protein phosphatase, and the students and fellows who joined Eddy in the 1960s spawned both fields. This world of protein phosphorylation was about to charge onto the world stage, and 1971 was a critical year of migrations (Fig. 2). Philip Cohen moved to the University of Dundee in 1971, having spent 2 years as a postdoctoral fellow in Eddys laboratory. Tony Hunter, with his focus on protein synthesis, moved in 1971 from the Biochemistry Department in Cambridge to the newly formed Salk Institute. I (S.S.T.), with my focus on protein structure and function, came as a postdoctoral fellow from the LMB in Cambridge to Nate Kaplans laboratory at the University of California, San Diego. Jack Dixon, who later became a part of this network with his discovery that the virulence factor in Yersinia pestis was a tyrosine phosphatase (14), also joined Nate Kaplans laboratory as a postdoctoral fellow in 1971. Jacks discovery, along with Nick Tonks discovery of the PTPase (11), added an exciting new chapter to the last three decades of Eddys life, and Jack and Eddy also became close friends. Neither Tony nor I knew much about protein phosphorylation, but that would quickly change. My world, however, changed abruptly and became indelibly intertwined with Eddys and Eds in late 1971, when Nate put a PKA paper by Fritz Lipmann on my desk (15). By the end of the 1970s and early 1980s, an international network was in place that would educate many future generations, and Eddy and Ed not only nucleated this network but became our mentors and role models.

Laying the foundations for a network in 1971. From left to right: Jean-Pierre Changeux (Image credit: J.-P. Changeux, Emeritus professor Collge de France and Institut Pasteur, Paris, France), Tony Hunter (Image credit: Tony Hunter, University of Cambridge, Cambridge, United Kingdom), Susan Taylor (Image credit: MRC Laboratory of Molecular Biology, Cambridge, United Kingdom), and Philip Cohen (Image courtesy of Philip Cohen, University of Dundee, Dundee, United Kingdom).

Eddy was first and foremost a biochemist with extraordinary vision who used chemistry to discover the secrets that were embedded in proteins (16). Initially his passion remained focused on these two enzymes, the kinase and the phosphatase, as well as the protein kinase inhibitor (17), although eventually the phosphatases would dominate his world. Like Eddy, my focus was on protein chemistry and structure. While I looked at sites of covalent modification of the PKA C-subunit using affinity labeling (18), Eddy was mapping its phosphorylation sites (7). Eddy also worked closely with Ken Walsh and Ko Titani and, using classic and laborious protein chemistry, they sequenced not only the PKA C-subunit in 1981 (8) but also in rapid succession glycogen phosphorylase (19) and phosphorylase kinase (20). Eddy and his collaborators thus defined the chemical signatures of these key proteins well before cDNA cloning and sequencing became routine procedures. It was a monumental task. Although Src tyrosine kinasehad been cloned 2 years earlier, until the PKA sequence was elucidated no one knew what a protein kinase looked like. It was Eddys sequence of the PKA C-subunit that unambiguously showed that cancer biology and glycogen metabolism were part of the same lineage (21). A decade later, in 1991, we published the first structure of a protein kinase (22). Eddy was always searching for clues about function, like the phosphorylation sites and the inhibitory function that was embedded in the sequence of the PKA inhibitor, PKI (23, 24).

In the 1970s and 1980s, the annual Federation Meeting, which included the American Society of Biological Chemists (later in 1987 to become the American Society of Biochemistry and Molecular Biology), was the place where biochemists gathered each year to share their data. In the 1970s and 1980s, I also came to know the people in the world of protein phosphorylation, including the international players, through the Cyclic Nucleotide Gordon Research Conferences (GRCs) and through many meetings in Europe. This is where I first encountered Eddys world. I first met Philip Cohen and Shmuel Shaltiel, for example, at GRCs. Through Shmuel, who was also passionate about unraveling the secrets of the PKA C-subunit, and in this regard was my scientific soul mate, I was indirectly linked to Eddy. Eddy first met Shmuel in 1963 when Eddy not only spent time in Paris but also traveled to the relatively new Weizmann Institute in Israel, where Shmuel, a graduate student, met him at the airport (25). Eddy actually began that sabbatical year of 1963 with a CIBA Foundation meeting in London on Control of Glycogen Metabolism organized by his good friend, Bill Whelan. While his children were in boarding school in Switzerland, Bev and Eddy traveled to both France and Israel, so this year set the stage for many future international meetings. At these early conferences, the protein kinases, protein phosphatases, and cAMP, along with the G proteins that were just being discovered, were intertwined; they were all part of the same story. Ludwig Heilmeyer, who overlapped with Philip in Eddys laboratory in Seattle, moved in 1970 to Germany, and he organized many NATO Summer Schools on protein phosphorylation in Europe, and Eddy attended many of these European meetings. Friederich Herberg, Ludwigs graduate student, came to University of California, San Diego as my postdoctoral fellow in 1990. He is my single direct link to Eddys academic tree.

So, from the very beginning, our community was truly international and spawned many close personal friendships. The Salk/Fred Hutchinson Cancer Research Center meetings also quickly became a regular feature of our community. These many meetings indelibly established from the very beginning in the 1960s an international protein phosphorylation network. American Society for Biochemistry and Molecular Biology, Federation of American Societies for Experimental Biology, International Union of Biochemistry and Molecular Biology, Keystone Symposia, and the Biochemical Society as well as others, such as the 1993 Lorne Conference in Australia, would continue and solidify this tradition by sponsoring many symposia on protein phosphorylation, which continue to this day.

Eddy was a deep scholar whose love of science dominated the field. Interdisciplinary thinking was woven into all our minds from the beginning. Sharing of ideas and information was also an essential part of this community. Listening to students and fellows was always a deeply shared commitment. We all grew up with this philosophy and with Eddy as our role model. A joy of science and a joy of life in general always seemed to radiate from Eddy (Fig. 3), and we all acknowledged him as our unequivocal leader for over half a century. Evidence of this recognition and of our devotion for this remarkable man were the many birthday celebrations: the 65th in Pitlochry, Scotland, for Eddy and on Orchas Island for Ed; the Miami Winter Symposium in 1989 organized by his lifelong friend, Bill Whelan (26); many 80th birthday celebrations; and most special of all, the 100th birthday symposium in 2020, which unfortunately had to be virtual, where Eddy participated actively with his typical enthusiasm for all the talks and warm personal attributes. His tree of students and fellows exemplifies the breadth and diversity of his thinking, but he was mentor to so many more, and we will all miss him.

Dancing at the 100th American Society for Biochemistry and Molecular Biology Anniversary celebration in 2006. Eddy Fischer and Susan S. Taylor. Image credit: American Society of Biochemistry and Molecular Biology.

Author contributions: S.S.T., T.H., and J.-P.C. wrote the paper.

The authors declare no competing interest.

The rest is here:
A tribute to Eddy Fischer (April 6, 1920August 27, 2021): Passionate biochemist and mentor - pnas.org